

PROGRAM INDICATION	CLASS	ROUTE	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	MILESTONES
<b>Vurolenatide</b> Short Bowel Syndrome	Long-Acting GLP-1	Injectable					First patient dosed → early 2023
<b>NM-136</b> Targeted Obesity Disorders	Anti-GIP hu-mAb	Injectable					IND-enabling underway
<b>NM-102</b> Orphan Indication TBD	Tight Junction Microbiome Modulator	Oral					IND-enabling underway
<b>NM-003</b> Orphan Indication TBD	Long-Acting GLP-2	Injectable					IND-enabling underway
<b>Partnered*</b>							
<b>Larazotide</b> MIS-C	Tight Junction Regulator	Oral; Gut Restricted					

NOTE: All products are New Chemical Entities; 9 Meters holds global rights to all assets

\* Clinical trial being conducted by European Biomedical Research Institute of Salerno (EBRIS)

MIS-C = multisystem inflammatory syndrome in children;

GLP-1 = glucagon-like peptide-1; GLP-2 = glucagon-like peptide-2; GIP = glucose-dependent insulinotropic polypeptide; hu-mAb = humanized monoclonal antibody